One of them, the phenylalanine-4-hydroxylase Pah, appeared to be particularly interesting since it is a druggable gene that acts upstream of tyrosine-dopamine biosynthesis and since increased dopamine levels were previously associated with early HD phenotypes such as hyperkinesia [49]. The gene discussed is PAH; the disease is Huntington disease.